Evidence map›Paper›PMID 38667289›Full record

ReviewCells2024

Identity and Maturity of iPSC-Derived Oligodendrocytes in 2D and Organoid Systems.

Ella Zeldich, Sandeep Rajkumar

Open access · goldAbstract readReview
In one paragraph

Review in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Stem Cell-Based Therapies for Central Nervous System Demyelinating Diseases: Clinical Evidence, Therapeutic Niches, and Translational Boundaries.Medical science monitor : international medical journal of experimental and clinical research · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Brain organoids: A new tool for modelling of neurodevelopmental disorders.Journal of cellular and molecular medicine · 2024
    Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Ella ZeldichDepartment of Anatomy & Neurobiology, Boston University Chobanian and Avedesian School of Medicine, Boston, MA 02118, USA.
Sandeep RajkumarDepartment of Anatomy & Neurobiology, Boston University Chobanian and Avedesian School of Medicine, Boston, MA 02118, USA.ORCID 0000-0001-6634-4840
Boston University · US

Funding

The contribution of X-chromosome-linked genes to cellular phenotypes and AD-related pathology in Down SyndromeR21AG080269 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ZELDICH, ELLA · 2023 to 2024
$454k
Development of myelinating oligodendrocytes in Down syndromeR21HD098542 · NICHD · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ZELDICH, ELLA · 2019 to 2020
$454k
Epigenetic Determinants in Oligodendrocyte Maturation in Down SyndromeR21NS125469 · NINDS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI MEDALLA, MARIA, ZELDICH, ELLA · 2022 to 2022
$454k
Studying Epigenetic Dysregulation in Down Syndrome Using Fluorescent Reporter Cell LinesR03NS126864 · NINDS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ZELDICH, ELLA · 2022 to 2023
$165k
NIA NIH HHS R21 AG080269NICHD NIH HHS R21 HD098542NINDS NIH HHS R03 NS126864NINDS NIH HHS R21 NS125469
6 · The paper itself

Abstract

Oligodendrocytes originating in the brain and spinal cord as well as in the ventral and dorsal domains of the neural tube are transcriptomically and functionally distinct. These distinctions are also reflected in the ultrastructure of the produced myelin, and the susceptibility to myelin-related disorders, which highlights the significance of the choice of patterning protocols in the differentiation of induced pluripotent stem cells (iPSCs) into oligodendrocytes. Thus, our first goal was to survey the different approaches applied to the generation of iPSC-derived oligodendrocytes in 2D culture and in organoids, as well as reflect on how these approaches pertain to the regional and spatial fate of the generated oligodendrocyte progenitors and myelinating oligodendrocytes. This knowledge is increasingly important to disease modeling and future therapeutic strategies. Our second goal was to recap the recent advances in the development of oligodendrocyte-enriched organoids, as we explore their relevance to a regional specification alongside their duration, complexity, and maturation stages of oligodendrocytes and myelin biology. Finally, we discuss the shortcomings of the existing protocols and potential future explorations.

Indexed as

Cell DifferentiationInduced Pluripotent Stem CellsOligodendrogliaOrganoidsAnimalsCell Culture TechniquesHumansMyelin Sheathbrain organoidsiPSCsmyelinoligodendrocytesregional patterning

Identifiers

PMID38667289
PMCPMC11049552
OpenAlexW4394813211

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.